Advertisement

Mycobacterial Disease

  • Anda Samson
  • Hiten Thaker
Chapter

Abstract

Mycobacterial disease remains as prevalent in the twenty-first century as it did many millennia ago. Current thinking on pathogenesis, clinical presentation, diagnosis, and treatment of mycobacterial diseases, both tuberculous and non-tuberculous (NTM) is described. Improved understanding of pathogenesis and the natural history of the infection has informed prevention strategies. Molecular techniques have led to faster diagnosis, identification, and treatment planning. Latent TB and the significance of NTM disease remains challenging. Treatment remains difficult, as a prolonged course of multiple antibiotics is still required, and thus increases the likelihood of developing drug-resistant TB.

Keywords

Tuberculosis Non-tuberculous mycobacteria Quantiferon test MDR-TB XDR-TB 

References

  1. 1.
    Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282(7):677–86.CrossRefPubMedGoogle Scholar
  3. 3.
    TB alert UK. 2016. Available at: https://www.tbalert.org.
  4. 4.
    Singh D, Sutton C, Woodcock A. Tuberculin test measurement: variability due to the time of reading. Chest. 2002;122(4):1299–301.CrossRefPubMedGoogle Scholar
  5. 5.
    National Institute for Health and Care Excellence. Tuberculosis NG33. NICE guideline published January 2016. Last updated May 2016. Available at: https://www.nice.org.uk/Tuberculosis.
  6. 6.
    Al Zahrani K, Al Jahdali H, Menzies D. Does size matter? Utility of size of tuberculin reactions for the diagnosis of mycobacterial disease. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1419–22.CrossRefPubMedGoogle Scholar
  7. 7.
    Redelman-Sidi G, Sepkowitz KA. IFN-gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med. 2013;188(4):422–31.CrossRefPubMedGoogle Scholar
  8. 8.
    Diel R, Loddenkemper R, Meywald-Walter K, Gottschalk R, Nienhaus A. Comparative performance of tuberculin skin test, QuantiFERON-TB-gold in tube assay, and T-spot.TB test in contact investigations for tuberculosis. Chest. 2009;135(4):1010–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Zijenah LS, Kadzirange G, Bandason T, Chipiti MM, Gwambiwa B, Makoga F, et al. Comparative performance characteristics of the urine lipoarabinomannan strip test and sputum smear microscopy in hospitalized HIV-infected patients with suspected tuberculosis in Harare, Zimbabwe. BMC Infect Dis. 2016;16:20.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hanifa Y, Fielding KL, Chihota VN, Adonis L, Charalambous S, Karstaedt A, et al. Diagnostic accuracy of lateral flow urine LAM assay for TB screening of adults with advanced immunosuppression attending routine HIV care in South Africa. PLoS One. 2016;11(6):e0156866.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bos JC, Smalbraak L, Macome AC, Gomes E, van Leth F, Prins JM. TB diagnostic process management of patients in a referral hospital in Mozambique in comparison with the 2007 WHO recommendations for the diagnosis of smear-negative pulmonary TB and extrapulmonary TB. Int Health. 2013;5(4):302–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Shapiro AE, Chakravorty R, Akande T, Lonnroth K, Golub JE. A systematic review of the number needed to screen to detect a case of active tuberculosis in different risk groups. Geneva: WHO; 2013.Google Scholar
  13. 13.
    World Health Organization. Updated WHO recommendations Xpert MTB/RIF test. Geneva: WHO; 2014.Google Scholar
  14. 14.
    Skoura E, Zumla A, Bomanji J. Imaging in tuberculosis. Int J Infect Dis. 2015;32:87–93.CrossRefPubMedGoogle Scholar
  15. 15.
    Dhooria S, Agarwal R, Aggarwal AN, Bal A, Gupta N, Gupta D. Differentiating tuberculosis from sarcoidosis by sonographic characteristics of lymph nodes on endobronchial ultrasonography: a study of 165 patients. J Thorac Cardiovasc Surg. 2014;148(2):662–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Sandgren A, Hollo V, van der Werf MJ. Extrapulmonary tuberculosis in the European Union and European Economic Area, 2002 to 2011. Euro Surveill. 2013;18(12):20431.PubMedGoogle Scholar
  17. 17.
    World Health Organization. WHO Xpert MTB/RIF implementation manual. Technical and operational ‘how-to’: practical considerations. Geneva: WHO; 2014.Google Scholar
  18. 18.
    Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577–87.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Chahed H, Hachicha H, Berriche A, Abdelmalek R, Mediouni A, Kilani B, et al. Paradoxical reaction associated with cervical lymph node tuberculosis: predictive factors and therapeutic management. Int J Infect Dis. 2016;54:4–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016;4:CD002244.PubMedGoogle Scholar
  21. 21.
    Husain AA, Daginawala HF, Singh L, Kashyap RS. Current perspective in tuberculosis vaccine development for high TB endemic regions. Tuberculosis (Edinb). 2016;98:149–58.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of InfectionHull and East Yorkshire Hospitals, Castle Hill HospitalCottinghamUK

Personalised recommendations